GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Assertio Holdings Inc (NAS:ASRT) » Definitions » Net-Net Working Capital

Assertio Holdings (Assertio Holdings) Net-Net Working Capital : $-0.16 (As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Assertio Holdings Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Assertio Holdings's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $-0.16.

The industry rank for Assertio Holdings's Net-Net Working Capital or its related term are showing as below:

ASRT's Price-to-Net-Net-Working-Capital is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.83
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Assertio Holdings Net-Net Working Capital Historical Data

The historical data trend for Assertio Holdings's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assertio Holdings Net-Net Working Capital Chart

Assertio Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.46 -6.62 -3.37 -1.70 -0.22

Assertio Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.94 -0.71 -0.44 -0.22 -0.16

Competitive Comparison of Assertio Holdings's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, Assertio Holdings's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assertio Holdings's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Assertio Holdings's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Assertio Holdings's Price-to-Net-Net-Working-Capital falls into.



Assertio Holdings Net-Net Working Capital Calculation

Assertio Holdings's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(73.441+0.75 * 47.663+0.5 * 37.686-148.416
-0-0)/94.6685
=-0.22

Assertio Holdings's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

Net-Net Working Capital(Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(80.743+0.75 * 42.61+0.5 * 38.602-147.471
-0-0)/95.1154
=-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Assertio Holdings  (NAS:ASRT) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Assertio Holdings Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Assertio Holdings's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Assertio Holdings (Assertio Holdings) Business Description

Traded in Other Exchanges
N/A
Address
100 South Saunders Road, Suite 300, Lake Forest, IL, USA, 60045
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Executives
Daniel A. Peisert director, officer: President & CEO C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Paul Schwichtenberg officer: SVP and CFO 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Ajay Patel officer: SVP and CAO 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Sam Schlessinger officer: SVP, General Counsel 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FORREST IL 60045
William Mckee director
Jeff L Vacirca director 4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Heather L Mason director 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Crg Partners Iii - Parallel Fund (a) L.p. 10 percent owner C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Mark Strobeck officer: EVP & Chief Operating Officer 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Crg Partners Iii L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Andrea Heslin Smiley director 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Megan C. Timmins officer: SVP, Gen Csl & Sec 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Crg Partners Iii - Parallel Fund B (cayman) L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002

Assertio Holdings (Assertio Holdings) Headlines

From GuruFocus